GHRS (GHRS) Stock Price & Analysis
GHRS (GHRS) fell 1.27% to USD 27.28 as of July 25, 2026 at 15:03 UTC, according to Nexqual real-time market data.
GHRS last closed at USD 27.63; the session ranged USD 26.75–28.1 on volume of 163,864 shares. Market capitalization is $1.87B, with a 52-week range of USD 11.32–31 (NGM). Source: Nexqual, July 25, 2026 at 15:03 UTC.
Key Statistics (as of July 25, 2026 at 15:03 UTC)
| Price | USD 27.28 |
|---|---|
| Change | ▼ 1.27% (down) |
| Previous Close | USD 27.63 |
| Open | USD 28.1 |
| Day Range | USD 26.75 – 28.1 |
| 52-Week Range | USD 11.32 – 31 |
| Volume | 163,864 shares |
| Market Cap | $1.87B |
| Exchange | NGM |
Technical Analysis (GHRS)
Nexqual's technical model rates GHRS "BUY" based on 4 bullish and 1 bearish signals across 125 daily candles, as of July 25, 2026 at 15:03 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.75 (neutral) |
| vs SMA50 | Above (USD 24.31) |
| MACD | 1.13 (positive) |
Analyst Ratings (GHRS)
Wall Street analysts rate GHRS "Strong Buy" based on 8 analysts, with a mean price target of USD 39.5 (range USD 32–65), per Nexqual as of July 25, 2026 at 15:03 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 39.5 |
| High Target | USD 65 |
| Low Target | USD 32 |
| Buy / Hold / Sell | 9 / 0 / 0 |
Earnings (GHRS)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD -0.32 |
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.31 vs est -0.26 ▼ miss |
| 2025-12-31 | USD -0.22 vs est -0.27 ▲ beat |
| 2025-09-30 | USD -0.23 vs est -0.23 ▼ miss |
| 2025-06-30 | USD -0.15 vs est -0.2 ▲ beat |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Financials & Fundamentals (GHRS)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -19.67% |
| Debt / Equity | 0.16 |
| Current Ratio | 23.04 |
| Total Cash | $267.32M |
| Total Debt | $432,000 |
| Free Cash Flow | $-32.74M |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Financial Health Score (GHRS)
Nexqual rates GHRS's overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 15:03 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $267M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$46M |
| Efficiency | Critical — ROE -20%, ROA -14.0% |
Ownership (GHRS)
| Insider Ownership | +24.23% |
|---|---|
| Institutional Ownership | +70.22% |
| Shares Outstanding | 68.61M |
| Float | 26.72M |
| Short % of Float | +7.24% |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Leadership (GHRS)
GHRS is led by Velichka Valcheva M.D., M.Sc. (age 50), Chief Executive Officer, per Nexqual as of July 25, 2026 at 15:03 UTC.
| Chief Executive Officer | Velichka Valcheva M.D., M.Sc. (age 50) |
|---|---|
| Co-Founder & Non-Executive Chairman of the Board | Florian Schonharting M.Sc. (Econ) (age 56) |
| Vice President of Finance | Julie Ryan F.C.A. (age 39) |
| Chief Operating Officer | Aaron Cameron (age 40) |
Major Backers & Investors (GHRS)
Notable institutional backers of GHRS include Lynx1 Capital Management Lp, BVF Inc., RA Capital Management, L.P., according to Nexqual as of July 25, 2026 at 15:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Lynx1 Capital Management Lp | 15.69% |
| BVF Inc. | 12.61% |
| RA Capital Management, L.P. | 11.19% |
| RTW Investments LP | 8.65% |
| FMR, LLC | 7.49% |
| Fidelity | 4.36% |
| Avoro Capital Advisors LLC | 2.62% |
| Toronto Dominion Bank | 2.04% |
Source: Nexqual, July 25, 2026 at 15:03 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ATAI | AtaiBeckley Inc. | USD 7.18 | ▲ 0% |
| GLUE | Monte Rosa Therapeutics, Inc. | USD 22.78 | ▼ 4.25% |
| HELP | Cybin Inc. | USD 7.62 | ▼ 2.56% |
| CMPS | COMPASS Pathways Plc - American | USD 11.26 | ▼ 5.62% |
| JBIO | Jade Biosciences, Inc. | USD 20.08 | ▲ 1.16% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 15:03 UTC. This page is informational and not investment advice.